Project description
Towards safer pharmaceuticals
Pharmaceuticals, including therapeutic antibodies, proteins and nanotechnology formulations, sometimes lead to severe and life-threatening conditions known as hypersensitivity reactions (HR). These emerge either due to a real allergic reaction driven by the release of IgE or because of a pseudoallergic condition triggered by the non-specific activation of the complement system. The latter triggers a massive acute inflammatory response associated with the release of cytokines, anaphylatoxins and cell-killing complexes. The EU-funded IMMUNOASSAYS project proposes to develop and evaluate promising biomarkers capable of discriminating between the different types of HR. These biomarkers could be employed for the safety assessment of new pharmaceuticals.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesbasic medicinepathology
- medical and health sciencesclinical medicineallergology
Programme(s)
Funding Scheme
MSCA-IF-EF-SE - Society and Enterprise panel
Coordinator
53359 Rheinbach
Germany
See on map